- Home
- TRX vs FBRX Comparison
TRX vs FBRX Comparison
Compare TRX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- FBRX
- Stock Information
- Founded
- TRX 1990
- FBRX N/A
- Country
- TRX Canada
- FBRX United States
- Employees
- TRX N/A
- FBRX 11
- Industry
- TRX
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- FBRX Health Care
- Exchange
- TRX Nasdaq
- FBRX Nasdaq
- Market Cap
- TRX 92.1M
- FBRX 37.2M
- IPO Year
- TRX N/A
- FBRX N/A
- Fundamental
- Price
- TRX $0.32
- FBRX $6.10
- Analyst Decision
- TRX Strong Buy
- FBRX Strong Buy
- Analyst Count
- TRX 2
- FBRX 4
- Target Price
- TRX $1.63
- FBRX $77.58
- AVG Volume (30 Days)
- TRX 382.3K
- FBRX 19.4K
- Earning Date
- TRX 04-11-2025
- FBRX 03-17-2025
- Dividend Yield
- TRX N/A
- FBRX N/A
- EPS Growth
- TRX N/A
- FBRX N/A
- EPS
- TRX 0.01
- FBRX N/A
- Revenue
- TRX $44,282,000.00
- FBRX N/A
- Revenue This Year
- TRX $68.64
- FBRX N/A
- Revenue Next Year
- TRX $22.37
- FBRX N/A
- P/E Ratio
- TRX $55.38
- FBRX N/A
- Revenue Growth
- TRX 16.51
- FBRX N/A
- 52 Week Low
- TRX $0.28
- FBRX $4.11
- 52 Week High
- TRX $0.49
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- TRX 44.39
- FBRX 22.34
- Support Level
- TRX $0.29
- FBRX $5.71
- Resistance Level
- TRX $0.34
- FBRX $9.90
- Average True Range (ATR)
- TRX 0.01
- FBRX 0.91
- MACD
- TRX 0.00
- FBRX -0.11
- Stochastic Oscillator
- TRX 25.50
- FBRX 1.94
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. Its projects include the Buckreef project, and Itetemia Gold project whereas, its exploration stage project consists of the Lunguya project and the Luhala project.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).